Navigation path

Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information

Recombinant human rod-derived cone viability factor

EU orphan designation number: EU/3/07/500
Active ingredient: Recombinant human rod-derived cone viability factor
Indication: Treatment of retinitis pigmentosa
Sponsor: Fovea Pharmaceuticals SA
Institut de la Vision, 17 rue Moreau, 75012 Paris, France

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
03/12/2007 Orphan designation EMEA/OD/075/07 (2007)6020 of 29/11/2007
25/02/2009 Change of name and/or address of sponsor
30/07/2014 Removal of orphan designation from Community Register